Clinical trial NCT02402764: Phase 2 Trial of Selinexor (KPT-330) for Metastatic Triple Negative Breast Cancer (TNBC)
Official title: Investigator-Initiated Phase 2 Clinical Trial of Selinexor (KPT-330) for the Treatment of Metastatic Triple Negative Breast Cancer
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Breast Cancer
Keywords: Triple Negative Breast Cancer (TNBC)
Breast - Female
Breast - Male
Metastatic Triple Negative Breast Cancer
Receptor Tyrosine-protein Kinase erbB-2 (HER2) Negative
Erythroblastosis virus oncogene B (erbB)
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute
Sponsor class: OTHER
Collaborators: name: Karyopharm Therapeutics Inc
First posted: 2015-03-30
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The main purpose of this study is to see whether the combination of selinexor (KPT-330) can help people with triple negative breast cancer (TNBC). Researchers also want to study the safety and tolerability of Selinexor in TNBC patients.


Eligibility criteria: Inclusion Criteria:

* Histologically confirmed triple negative breast cancer (TNBC), defined as negative immunohistochemical staining for estrogen and progesterone receptors (≤5% of nuclei positive by IHC) and receptor tyrosine-protein kinase erbB-2 (HER2) negative (IHC 0-1+ or HER2-neu negative according to American Society of Clinical Oncology; College of American Pathologists (ASCO-CAP) HER2 Test Guideline Recommendations)
* Written informed consent in accordance with federal, local, and institutional guidelines
* Body surface area ≥1.4 m\^2
* Age ≥18 years
* Estimated life expectancy of \>3 months at study entry
* TNBC must be either locally recurrent or metastatic. Locally recurrent disease must not be amenable to surgical resection or radiation with curative intent.
* Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
* Documented disease progression at study entry
* Must have received at least 1 chemotherapy regimens in the setting of metastatic disease
* Eastern Cooperative Oncology Group (ECOG) performance status of ≤2
* Adequate hematological function: Absolute neutrophil count (ANC) \> 1500/mm\^3, platelets count \>100,000mm\^3
* Adequate hepatic function within 14 days prior to Cycle 1 Day 1 (C1D1): total bilirubin \<2 times the upper limit of normal (ULN) (except patients with Gilbert's syndrome who must have a total bilirubin of \< 3 times ULN) and aspartate aminotransferase (AST), alanine aminotransferase (ALT) ≤2.5 x ULN. In the case of known (radiological and/or biopsy documented) liver metastasis, AST/ALT ≤5.0 times ULN is acceptable.
* Amylase and lipase ≤ 1.5 x ULN
* Adequate renal function within 14 days prior to C1D1: estimated creatinine clearance of ≥ 30 mL/min
* Women of child-bearing potential (WOCBP) must agree to use dual methods of contraception and have a negative serum pregnancy test at screening, and male participants must use an effective barrier method of contraception if sexually active with a female of child-bearing potential. For both male and female participants, effective methods of contraception must be used throughout the study and for 3 months following the last dose. To be considered of non-childbearing potential, postmenopausal women must be amenorrheic for at least 12 months naturally (not in the setting of post chemotherapy) or participants must be surgically sterile.
* Must have received prior anthracycline and taxane therapy unless clinically contraindicated

Exclusion Criteria:

* Significant medical illness that in the investigator's opinion cannot be adequately controlled with appropriate therapy or would compromise the participant's ability to tolerate this therapy
* Women who are pregnant or lactating
* Radiation, chemotherapy, or immunotherapy or any other approved anticancer therapy ≤2 weeks prior to cycle 1 day 1
* Major surgery within 4 weeks before Day 1
* Unstable cardiovascular function: Electrocardiogram (ECG) abnormalities requiring treatment, or congestive heart failure (CHF) of New York Hearth Association (NYHA) Class ≥3; myocardial infarction (MI) within 3 months
* Uncontrolled infection requiring parenteral antibiotics, antivirals, or antifungals within one week prior to first dose. Potential participants with controlled infection or on prophylactic antibiotics are permitted in the study.
* Known history of HIV
* Known active hepatitis A, B, or C infection that requires treatment
* Any underlying condition that would significantly interfere with the absorption of an oral medication
* Grade \>2 peripheral neuropathy at baseline (within 14 days prior to cycle 1 day 1)
* Participation in an investigational anti-cancer study within 3 weeks prior to Cycle 1 Day 1
* Coagulation problems and active major bleeding within 4 weeks prior to C1D1 (peptic ulcer, epistaxis, spontaneous bleeding)
* Active central nervous system (CNS) malignancy. Asymptomatic small lesions are not considered active. Treated lesions may be considered inactive if they are stable for at least 3 months.
* Radiation, chemotherapy, or immunotherapy or any other anticancer therapy ≤ 2 weeks prior to Cycle 1 Day 1 or radio-immunotherapy ≤ 4 weeks prior to Cycle 1 Day 1
* Have not recovered to Grade ≤ 1 or to their baseline from clinically significant adverse effects

Primary outcomes:
measure: Clinical Benefit Rate
timeFrame: Up to 10 months
Secondary outcomes:
measure: Best Overall Response (OR)
timeFrame: Up to 10 months
measure: Duration of Overall Response
timeFrame: Up to 10 months
measure: Progression-Free Survival (PFS)
timeFrame: Up to 10 months
measure: Overall Survival (OS)
timeFrame: End of post-treatment 12 month follow-up, up to 24 months per participant
Other outcomes:
Locations:
city: Tampa
country: United States
facility: H. Lee Moffitt Cancer Center and Research Institute
state: Florida
Study officials:
affiliation: H. Lee Moffitt Cancer Center and Research Institute
name: Hyo S. Han, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Shafique M, Ismail-Khan R, Extermann M, Sullivan D, Goodridge D, Boulware D, Hogue D, Soliman H, Khong H, Han HS. A Phase II Trial of Selinexor (KPT-330) for Metastatic Triple-Negative Breast Cancer. Oncologist. 2019 Jul;24(7):887-e416. doi: 10.1634/theoncologist.2019-0231. Epub 2019 Apr 17.